|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2:A project of the Kyushu University Liver Disease Study Group显示文摘瞄准:决定一座干扰素高山的功效哈并且为感染遗传型 2 的丙肝病毒(HCV ) 的日本病人的 ribavirin 联合治疗,多中心研究回顾地被分析。方法:总共,有 HCV 遗传型 2 的 173 个病人每天一个星期和 ribavirin 的 600-800 mg 为 24 wk 三次皮下地收到 interferon-alpha。结果:总的来说持续的 virological 反应(SVR ) ,在浆液的定义同样无法发现的 HCV RNA,在治疗的结束以后的 24 wk,在 84.4% 显著地高,(146/173 ) 由 intention-to-treat 分析。在 SVR 的有效差量有或没有 ribavirin (46.9% 对 92.9%) 的中止在病人之间被发现,但是没有差别有或没有 ribavirin 的剂量减小在那些之间被发现。在 SVR 的有效差量也与 16 或更与不到 16 wk 和病人在病人之间被发现 ribavirin 治疗(34.8% 对 92.0%) 的星期。结论:24-wk 干扰素和 ribavirin 治疗为有 HCV 遗传型 2 的日本病人是高度有效的。SVR 的重要预言者是 ribavirin 治疗的继续多达 16 个星期。 | Norihiro Furusyo Masaki Katoh Yuichi Tanabe Eiji Kajiwara Toshihiro Maruyama Junya Shimono Hironori Sakai Makoto Nakamuta Hideyuki Nomura Akihide Masumoto Shinji Shimoda Kazuhiro Takahashi Koichi Azuma Jun Hayashi Kyushu University Liver Disease Study Group | 2006 | World Journal of Gastroenterology2006，12，5： | 8 |
| 2 | Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study显示文摘 | Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Kazuhiro Takahashi Hideyuki Nomura Toshihiro Maruyama Yuichi Tanabe Takeaki Satoh Makoto Nakamuta Kazuhiro Kotoh Koichi Azuma Kazufumi Dohmen Shinji Shimoda Jun Hayashi | 2012 | Journal of Hepatology2012，，： | 3 |
| 3 | Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C显示文摘 | Norihiro Furusyo Eiichi Ogawa Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，2： | 2 |
| 4 | Nanoparticles in Emissions and Atmospheric Environment: Now and Future显示文摘 | Seishiro Hirano Hiroshi Nitta Yuichi Moriguchi Shinji Kobayashi Yoshinori Kondo Kiyoshi Tanabe Takahiro Kobayashi Shinji Wakamatsu Masatoshi Morita Satoshi Yamazaki | 2003 | Journal of Nanoparticle Research (-)2003，，3： | 1 |
| 5 | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy显示文摘 | Eiichi Ogawa Norihiro Furusyo Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，： | 1 |
| 6 | Pregabalin, S -(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model显示文摘 | Yuichi Takeuchi Keiko Takasu Hideki Ono Mitsuo Tanabe | 2007 | Neuropharmacology2007，，7： | 1 |
| 7 | Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C<!-- Doctopic: VH -->显示文摘 | Norihiro Furusyo Eiichi Ogawa Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，2： | 1 |
| 8 | Relationship between body surface area and ALT normalization after long-term lamivudine treatment显示文摘AIM: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation.METHODS: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249),two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA,as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT,albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed.RESULTS: For 1-year treatment, multivariate analysis revealed that BSA (P=0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBVDNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA(P = 0.0147) was the only factor for the biological effect,and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels.CONCLUSION: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA. | Makoto Nakamuta Shusuke Morizono Yuichi Tanabe Eiji Kajiwara Junya Shimono Akihide Masumoto Toshihiro Maruyama Norihiro Furusyo Hideyuki Nomura Hironori Sakai Kazuhiro Takahashi Koichi Azuma Shinji Shimoda Kazuhiro Kotoh Munechika Enjoji Jun Hayashi Kyushu University liver Disease Study Group | 2005 | World Journal of Gastroenterology2005，11，44： | 1 |
| 9 | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy<!-- Doctopic: VH -->显示文摘 | Eiichi Ogawa Norihiro Furusyo Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，： | 1 |
| 10 | Preparation of long sticky ends for universal ligation-independent cloning: Sequential T4 DNA polymerase treatments显示文摘 | Akira Tachibana Kazuo Tohiguchi Takayuki Ueno Yuichi Setogawa Ayako Harada Toshizumi Tanabe | 2009 | Journal of Bioscience and Bioengineering2009，，6： | 1 |
| 11 | Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C显示文摘AIM:To analyze the efficacy and safety of a combination therapy of pegylated interferon(PEG-IFN) α-2b plus ribavirin(RBV) in older Japanese patients(65 years or older) infected with hepatitis C virus(HCV).METHODS:This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk.RESULTS:At 24 wk after the end of combination therapy,the overall sustained virological response(SVR) for genotypes 1 and 2 were 40.7% and 79.6%,respectively.The SVR rate decreased signif icantly with age in each genotype,and was markedly reduced in genotype 1(P<0.001).Moreover,the SVR was significantly higher in patients with genotype 1 who were less than 65 years(47.3% of 685) than in those 65 years or older(22.9% of 253)(P<0.001) and was higher in patients with genotype 2 who were less than 65 years(82.9% of 252) than in those 65 years or older(65.6% of 61)(P=0.004).When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV,the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older(P<0.001).Adverse effects resulted in treatment discontinuation more often in patients with genotype 1(14.4%) than in patients with genotype 2(7.3%),especially by patients 65 years or older(24.1%).CONCLUSION:PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage. | Mosaburo Kainuma Norihiro Furusyo Eiji Kajiwara Kazuhiro Takahashi Hideyuki Nomura Yuichi Tanabe Takeaki Satoh Toshihiro Maruyama Makoto Nakamuta Kazuhiro Kotoh Koichi Azuma Junya Shimono Shinji Shimoda Jun Hayashi | 2010 | World Journal of Gastroenterology2010，16，35： | 1 |
| 12 | Characterization of myofibroblasts in chronic thromboembolic pulmonary hypertension显示文摘 | Miki Maruoka Seiichiro Sakao Masashi Kantake Nobuhiro Tanabe Yasunori Kasahara Katsushi Kurosu Yuichi Takiguchi Masahisa Masuda Ichiro Yoshino Norbert F. Voelkel Koichiro Tatsumi | 2011 | International Journal of Cardiology2011，，2： | 1 |
| 13 | Long-term lamivudine treatment for chronic,hepatitis B in Japanese patients:A project of Kyushu University Liver Disease Study显示文摘瞄准:与长期的肝炎 B 决定很多日本病人的长期的 lamivudine 治疗的功效。方法:在这回顾,多中心试用,有长期的肝炎 B 的 318 个日本病人每天为多达 36 收到了 lamivudine 的 100 mg (中部 21 ) 瞬间。Virological 反应是到浆液 HBV DNA 水平的衰落不到 3.7 木头 copies/mL。当浆液 HBV DNA 的再现在 treatment.RESULTS 期间铺平最小到超过 10 褶层, Virological 突破被定义:Lamivudine 在 6 瞬间在 318 个病人中的 86.8% 个生产了 virological 反应,在在 12 瞬间的 252 个病人中的 80.2% 个,在在 24 瞬间的 133 个病人中的 69.2% 个,并且在在 36 瞬间的 28 个病人中的 53.6% 个。向前逐步的逻辑回归分析证明 HBV DNA 铺平不到 6.8 木头 copies/mL ( P<0.0001 ), HBeAg 否定性( P<0.0001 ), 100 x 10 的一个血小板计数( 9 )在基线的 /L 或更多( P=0.0162 ),并且超过 3.2 木头 copies/mL 的 HBV DNA 水平的衰落在治疗( P=0.0003 )的开始以后在 3 瞬间作为与基线相比铺平显著地与 virological 反应被联系。在有 virological 回答的病人之中, virological 突破在在 1 瞬间 virologically 反应了的 19 个病人中的5.3%个被看见,在在 3 瞬间的 203 个病人中的20.7%个,在在 6 瞬间的 51 个病人中的27.5%个,在在 9 瞬间的 12 个病人中的33.3%个,并且在在 >=5 瞬间的 3 个病人的100%。virological 突破与推迟的 virological response.CONCLUSION 在病人更经常显著地被发现:Lamivudine 治疗能在大多数测试日本病人压制浆液 HBV DNA。没有 HBeAg,长期的功效可能在基线在病人被看见,当肝硬化不在时,并且在有在 HBV 的衰落的病人, DNA 此后不久铺平治疗的开始。 | Norihiro Furusyo Hiroaki Takeoka Kazuhiro Toyoda Masayuki Murata Yuichi Tanabe Eiji Kajiwara Junya Shimono Akihide Masumoto Toshihiro Maruyama Hideyuki Nomura Makoto Nakamuta Kazuhiro Takahashi Shinji Shimoda Koichi Azuma Hironori Sakai Jun Hayashi | 2006 | World Journal of Gastroenterology2006，12，4： | 1 |
| 14 | Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial显示文摘 | Takaki Yoshikawa Kazuaki Tanabe Kazuhiro Nishikawa Yuichi Ito Takanori Matsui Yutaka Kimura Naoki Hirabayashi Shoki Mikata Makoto Iwahashi Ryoji Fukushima Nobuhiro Takiguchi Isao Miyashiro Satoshi Morita Yumi Miyashita Aakira Tsuburaya Junichi Sakamoto | 2014 | Annals of Surgical Oncology2014，，1： | 1 |
| 15 | Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection显示文摘 | Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Makoto Nakamuta Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2014 | Antiviral Research2014，，： | 1 |
| 16 | Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial显示文摘 | Takaki Yoshikawa Kazuaki Tanabe Kazuhiro Nishikawa Yuichi Ito Takanori Matsui Yutaka Kimura Naoki Hirabayashi Shoki Mikata Makoto Iwahashi Ryoji Fukushima Nobuhiro Takiguchi Isao Miyashiro Satoshi Morita Yumi Miyashita Aakira Tsuburaya Junichi Sakamoto | 2014 | Annals of Surgical Oncology2014，，1： | 1 |
| 17 | Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth显示文摘 | Nomiyama Takashi Kawanami Takako Irie Shinichiro Hamaguchi Yuriko Terawaki Yuichi Murase Kunitaka Tsutsumi Yoko Nagaishi Ryoko Tanabe Makito Morinaga Hidetaka Tanaka Tomoko Mizoguchi Makio Nabeshima Kazuki Tanaka Masatoshi Yanase Toshihiko | 2014 | Diabetes2014，，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员